Double-Blind, Placebo-Controlled Proof of Concept Study in Youth With Fragile X Syndrome
Status: Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 17 Feb 2019
Price : $35 *
At a glance
- Drugs Acamprosate (Primary)
- Indications Fragile X syndrome
- Focus Proof of concept; Therapeutic Use
- 08 Feb 2019 Planned End Date changed from 1 Feb 2018 to 1 Jun 2020.
- 08 Feb 2019 Planned primary completion date changed from 1 Feb 2018 to 1 Jun 2019.
- 08 Feb 2019 Status changed from recruiting to active, no longer recruiting.